Log in

Relevant bibliographies by topics / Interruption of pregnancy / Journal articles

Journal articles on the topic 'Interruption of pregnancy'

To see the other types of publications on this topic, follow the link: Interruption of pregnancy.

Author: Grafiati

Published: 9 March 2023

Last updated: 10 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Interruption of pregnancy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cho, Seio Beom, Chul Joong Kim, Myung Gyu Kim, Young Rahn Lee, In Ho Cha, Nam Jun Lee, and Kyoo Byung Chung. "Transcervical interruption of ectopic pregnancy." Journal of the Korean Radiological Society 29, no. 3 (1993): 492. http://dx.doi.org/10.3348/jkrs.1993.29.3.492.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Bugalho, Antonio, Cassimo Bique, Luisa Almeida, and Staffan Bergström. "Pregnancy Interruption by Vaginal Misoprostol." Gynecologic and Obstetric Investigation 36, no. 4 (1993): 226–29. http://dx.doi.org/10.1159/000292634.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Burhanuddin, A. F. M. "Interruption of Pregnancy by Indigenous Method." Journal of The Asian federation of Obstetrics and Gynaecology 5, no. 1 (May 24, 2010): 1–5. http://dx.doi.org/10.1111/j.1447-0756.1975.tb00021.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

David, Henry P. "Acceptability of Mifepristone for Early Pregnancy Interruption." Law, Medicine and Health Care 20, no. 3 (September 1992): 188–94. http://dx.doi.org/10.1111/j.1748-720x.1992.tb01187.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Bewley, Susan, and Andrew Shennan. "HYPITAT and the fallacy of pregnancy interruption." Lancet 375, no. 9709 (January 2010): 119. http://dx.doi.org/10.1016/s0140-6736(10)60043-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Edmonston, Barry. "Interruption of breastfeeding by child death and pregnancy." Social Biology 37, no. 3-4 (September 1990): 233–50. http://dx.doi.org/10.1080/19485565.1990.9988763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Deliveliotis, Ch, B. Argyropoulos, M. Chrisofos, and C. A. Dimopoulos. "Shockwave Lithotripsy in Unrecognized Pregnancy: Interruption or Continuation?" Journal of Endourology 15, no. 8 (October 2001): 787–88. http://dx.doi.org/10.1089/089277901753205744.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Agostino, Bengtsson, and V. Wahlberg. "Interruption of Pregnancy: Motives, Attitudes and Contraceptive Use." Gynecologic and Obstetric Investigation 32, no. 3 (1991): 139–43. http://dx.doi.org/10.1159/000293015.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Rodríguez-Calvo, María Sol, Isabel María Martínez-Silva, José Luis Soto, Luis Concheiro, and José Ignacio Muñoz-Barús. "University students’ attitudes towards Voluntary Interruption of Pregnancy." Legal Medicine 14, no. 4 (July 2012): 209–13. http://dx.doi.org/10.1016/j.legalmed.2012.02.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Brandão, Andreia, Eliana Pereira, Filipe Portela, Manuel Filipe Santos, António Abelha, and José Machado. "Managing Voluntary Interruption of Pregnancy Using Data Mining." Procedia Technology 16 (2014): 1297–306. http://dx.doi.org/10.1016/j.protcy.2014.10.146.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bygdeman, M., and P. F. A. Vanlook. "7 Anti-progesterones for the interruption of pregnancy." Baillière's Clinical Obstetrics and Gynaecology 2, no. 3 (September 1988): 617–29. http://dx.doi.org/10.1016/s0950-3552(88)80048-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Krohn, M., A. Hardy-Fairbanks, J. Hansen, and C. Stockdale. "Midtrimester pregnancy interruption: providers’ perspectives, practice and knowledge." Contraception 90, no. 3 (September 2014): 351. http://dx.doi.org/10.1016/j.contraception.2014.05.200.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Abramchenko, V. V., A. G. Savitsky, and O. V. Kaplenko. "Pitocin receptorsand efficiency of labor activity." Journal of obstetrics and women's diseases 47, no. 3-4 (December 15, 1998): 82–87. http://dx.doi.org/10.17816/jowd87475.

Full text

Abstract:

Pitocin is the most widely used preparation for advance pregnancy interruption. In the review of the literature the modern data is given about a role of pitocin receptors in successful labor induction and amplification of labor activity. There is also given data on the regulation opportunity of pitocin receptors level with estrogens, prostaglandines and their significance in OB practice. This data needs to be taken into account for drugs development to advance the pregnancy interruption.

APA, Harvard, Vancouver, ISO, and other styles

14

Komlichenko, Е. V., L. H. Kim, E. L. Nezhentseva, L. V. Ivanova, and V. F. Bezhenar. "Peculiarities of pregnancy interruption in female patients with syphilis." Journal of obstetrics and women's diseases 51, no. 2 (April 14, 2002): 50–53. http://dx.doi.org/10.17816/jowd90393.

Full text

Abstract:

One presented in this article the analysis of pregnancy interruption peculiarities in 14O women with various syphilis forms. Peculiarities of the reproductive and social anamnesis were shown in mentioned categories of women. Regularities between syphilis morbidity and indices of reproductive health of women were detected. Elaboration perspective ways of syphilis and pregnancy problem were outlined.

APA, Harvard, Vancouver, ISO, and other styles

15

Heske, E. J. "Pregnancy Interruption by Strange Males in the California Vole." Journal of Mammalogy 68, no. 2 (May 26, 1987): 406–10. http://dx.doi.org/10.2307/1381485.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Ramin, Kirk D., Paul L. Ogburn, Diana R. Danilenko, and Patrick S. Ramsey. "High-Dose Oral Misoprostol for Mid-Trimester Pregnancy Interruption." Gynecologic and Obstetric Investigation 54, no. 3 (2002): 176–79. http://dx.doi.org/10.1159/000067889.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Faundes, A., L. C. Santos, M. Carvalho, and C. Gras. ""Post-abortion Complications after Interruption of Pregnancy with Misoprostol"." Studies in Family Planning 27, no. 5 (September 1996): 290. http://dx.doi.org/10.2307/2138004.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Koopmans, Corine M., Ben WJ Mol, Joris AM van der Post, and Maria G. van Pampus. "HYPITAT and the fallacy of pregnancy interruption – Authors' reply." Lancet 375, no. 9709 (January 2010): 119–20. http://dx.doi.org/10.1016/s0140-6736(10)60044-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

19

Haj Kacem, H., N. Ayadi, J. Masmoudi, L. Mnif, R. Marwan, A. Feki, and A. Jaoua. "P02-175 - Voluntary interruption of pregnancy in unmarried girls." European Psychiatry 25 (2010): 799. http://dx.doi.org/10.1016/s0924-9338(10)70790-2.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

Ferreira, Manuela, Bruno Fernandes, João Duarte, and Cláudia Chaves. "Attitudes of Women Regarding the Voluntary Interruption of Pregnancy." Procedia - Social and Behavioral Sciences 171 (January 2015): 104–12. http://dx.doi.org/10.1016/j.sbspro.2015.01.095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Scaravilli, G., D. Raimondo, S. Simeone, A. Menditto, S. Capuano, E. De Crescenzo, R. Bonafiglia, and C. Balbi. "T08-O-17 Sexuality after voluntary interruption of pregnancy." Sexologies 17 (April 2008): S110. http://dx.doi.org/10.1016/s1158-1360(08)72818-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Faúndes, A., L. C. Santos, M. Carvalho, and C. Gras. "Post-abortion complications after interruption of pregnancy with misoprostol." Advances in Contraception 12, no. 1 (March 1996): 1–9. http://dx.doi.org/10.1007/bf01849540.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Juma, Matthews, Solveig Ericson, Dawn Fun Eng, Sandip Acharya, Darshan Wariabharaj, Tina Owugah, Bettine Avenia, and Oleg Zernovak. "Prospective, observational registry of branded imatinib (IM) and nilotinib (NIL) exposure in pregnant women: Voluntary post-authorization safety study." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): TPS6638. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps6638.

Full text

Abstract:

TPS6638 Background: Family planning decisions for cancer patients of childbearing age are impacted by their diagnosis. IM and NIL are category D drugs (demonstrated risk to the fetus based on mechanism of action and findings in animals; however, the benefits of therapy may outweigh the potential risk to the fetus); women should be advised not to become pregnant when taking these drugs. Limited data exist concerning safety of these drugs during pregnancy and consequences of interrupting treatment. The registry does not recommend patients receiving IM or NIL become pregnant, but serves only to document exposures that occur, and collect information on pregnancy outcome, maternal course of disease, and infant follow-up. Methods: The registry intends to enroll 150 women (≥18 years) treated with branded IM and NIL within 6 mo before or during pregnancy (generic IM and NIL reports are excluded). Schedule of visits and treatment is according to local standard of care. Women are divided into 2 exposure cohorts: 1) pregnancy/fetal: received tyrosine kinase inhibitors (TKIs) within 14 d of conception or at any time during pregnancy; 2) interrupted TKI: received TKIs within 6 mo before conception but interrupted TKIs in preparation for/due to pregnancy. To identify signals of teratogenicity, the registry uses a general population baseline rate of birth defects, and the prevalence of defects in cohorts 1 and 2 may be compared. Cases are quantitatively analyzed for the emergence of unique defects or patterns of defects. Primary objective: monitor TKI-exposed pregnancies to estimate the prevalence of birth defects (calculated by dividing number of birth defects by total number of exposed live births from cohort 1). Secondary objectives are to: 1) determine the impact of treatment interruption on maternal disease status; 2) assess and estimate the prevalence of serious adverse pregnancy outcomes; and 3) assess and estimate the prevalence of developmental delays and functional deficits among infants during the first year of life. Maternal disease status is analyzed, comparing disease status at registration, pregnancy outcome, and 1 y after birth, stratified by length of TKI interruption.

APA, Harvard, Vancouver, ISO, and other styles

24

Reich-Schupke, Leiste, Moritz, Altmeyer, and Stücker. "Sclerotherapy in an undetected pregnancy - a catastrophe?" Vasa 41, no. 4 (July 1, 2012): 243–47. http://dx.doi.org/10.1024/0301-1526/a000199.

Full text

Abstract:

According to the guidelines and the manufacturers information, pregnancy is a contraindication for sclerotherapy with Polidocanol. However, in some cases sclerotherapy has been conducted in a period when the pregnancy is not known by the patient. When pregnancy is diagnosed, patients and gynecologists often ask the phlebologist if there is an indication for the interruption of pregnancy. Up to now, there is only rare information on sclerotherapy, polidocanol and pregnancy. Current knowledge is summed up in this article together with case reports. The existing case reports and mainly retrospective case series on intended or accidentally conducted sclerotherapy with common sclerosants and doses show no increased risk for the mother and the unborn child. However, in view of the limited literature data available and the high probability for spontaneous regression of varicose veins postpartum, sclerotherapy should be avoided in pregnancy, if possible. Conservative measures during pregnancy or an elimination of varicose veins before pregnancy should be preferred. In single cases e.g. painful genitoanal varices, the use of sclerotherapy can be helpful even during pregnancy. Thereby, a very thorough clarification of the mother with a final written consent and an implementation according to the guidelines are especially important. According to the current data, there is no reason for an interruption after a sclerotherapy that has been conducted during undetected pregnancy.

APA, Harvard, Vancouver, ISO, and other styles

25

Kosheleva, N. G., P. S. Buzurukova, T. P. Vosheva, and T. M. Crawl. "Features Central Blood Circulation at Women with Normal and Pathological Current of Pregnancy." Journal of obstetrics and women's diseases 51, no. 2 (April 14, 2002): 38–42. http://dx.doi.org/10.17816/jowd90380.

Full text

Abstract:

Features central blood circulation at 386 women are investigated: 6O healthy not pregnant women, 53 healthy pregnant, 147 women with threat of interruption of pregnancy and 126 with gestosis. Distribution on types of central blood circulation at healthy pregnant differed from healthy not pregnant. The increase of frequency eucinetic blood circulation in 2 times and demotion of frequency hypocinetic blood circulation in 3 times took place. At development gestosis the increase of frequency hypocinetic blood circulation was observed: at hypostases pregnant in 3 times, and at nephropathy in 6 times in comparison with healthy pregnant. At threat of interruption of pregnancy distribution pregnant on types is similar with not pregnant.

APA, Harvard, Vancouver, ISO, and other styles

26

Kiseleva, Elena Yuryevna, Marina Ivanovna Bazina, Antonina Timofeevna Egorova, and Svetlana Nikolaevna Zharskaya. "Experience of use of medicamental interruption of non-stabilating pregnancy." Interactive science, no. 9 (19) (September 21, 2017): 32–34. http://dx.doi.org/10.21661/r-463708.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Bugalho, Antonio, Cassimo Bique, Caetano Pereira, Ana Carla Granja, and Staffan Bergstrom. "Uterine evacuation by vaginal misoprostol after second trimester pregnancy interruption." Acta Obstetricia et Gynecologica Scandinavica 75, no. 3 (March 1996): 270–73. http://dx.doi.org/10.3109/00016349609047100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Sandstrøm, Ole, Lis Brooks, Anne Schantz, Jørgen Grinsted, Lotte Grinsted, JensDuelund Jacobsen, and StigPors Nielsen. "Interruption of early pregnancy with mifepristone in combination with gemeprost." Acta Obstetricia et Gynecologica Scandinavica 78, no. 9 (January 1999): 806–9. http://dx.doi.org/10.1080/j.1600-0412.1999.780913.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Cerveira, Nuno, and António Almeida. "Evidence-Based Criteria for Tyrosine Kinase Inhibitor Interruption in Pregnancy." Journal of Clinical Oncology 37, no. 1 (January 1, 2019): 89–90. http://dx.doi.org/10.1200/jco.18.00814.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

DENDRINOS, S., G. KALABALIKIS, E. MAKRAKIS, C. PAPASTERIADES, G. CREATSAS, and T. KATSORCHIS. "HLA-G in murine peripheral blood after interruption of pregnancy." Cell Biology International 29, no. 6 (June 2005): 402–7. http://dx.doi.org/10.1016/j.cellbi.2004.12.005.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Sandstrøm, Ole, Lis Brooks, Anne Schantz, Jørgen Grinsted, Lotte Grinsted, Jens Duelund Jacobsen, and Stig Pors Nielsen. "Interruption of early pregnancy with mifepristone in combination with gemeprost." Acta Obstetricia et Gynecologica Scandinavica 78, no. 9 (September 1999): 806–9. http://dx.doi.org/10.1034/j.1600-0412.1999.780913.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Sasse, Simone A., Bryna J. Harrington, Bethany L. DiPrete, Maganizo B. Chagomerana, Laura Limarzi Klyn, Shaphil D. Wallie, Madalitso Maliwichi, et al. "Factors associated with a history of treatment interruption among pregnant women living with HIV in Malawi: A cross-sectional study." PLOS ONE 17, no. 4 (April 19, 2022): e0267085. http://dx.doi.org/10.1371/journal.pone.0267085.

Full text

Abstract:

Introduction Long-term care engagement of women on antiretroviral therapy (ART) is essential to effective HIV public health measures. We sought to explore factors associated with a history of HIV treatment interruption among pregnant women living with HIV presenting to an antenatal clinic in Lilongwe, Malawi. Methods We performed a cross-sectional study of pregnant women living with HIV who had a history of ART interruption presenting for antenatal care. Women were categorized as either retained in HIV treatment or reinitiating care after loss-to-follow up (LTFU). To understand factors associated with treatment interruption, we surveyed socio-demographic and partner relationship characteristics. Crude and adjusted prevalence ratios (aPR) for factors associated with ART interruption were estimated using modified Poisson regression with robust variance. We additionally present patients’ reasons for ART interruption. Results We enrolled 541 pregnant women living with HIV (391 retained and 150 reinitiating). The median age was 30 years (interquartile range (IQR): 25–34). Factors associated with a history of LTFU were age <30 years (aPR 1.46; 95% CI: 1.33–1.63), less than a primary school education (aPR 1.25; CI: 1.08–1.46), initiation of ART during pregnancy or breastfeeding (aPR 1.49, CI: 1.37–1.65), nondisclosure of HIV serostatus to their partner (aPR 1.39, CI: 1.24–1.58), lack of awareness of partner’s HIV status (aPR 1.41, CI: 1.27–1.60), and no contraception use at conception (aPR 1.60, CI 1.40–1.98). Access to care challenges were the most common reasons reported by women for treatment interruption (e.g., relocation, transport costs, or misplacing health documentation). Conclusions Interventions that simplify the ART clinic transfer process, facilitate partner disclosure, and provide counseling about the importance of lifelong ART beyond pregnancy and breastfeeding should be further evaluated for improving retention in ART treatment of women living with HIV in Malawi.

APA, Harvard, Vancouver, ISO, and other styles

33

Soto, Maria Luisa Quintero, Cruz García Lirios, Sonia Sujell Velez Baez, and Sofia Lopez de Nava Tapia. "Confirmatory factorial model of the interruption of pregnancy against COVID-19." Advances in Health and Behavior 5, no. 1 (2022): 208–14. http://dx.doi.org/10.25082/ahb.2022.01.003.

Full text

Abstract:

The objective of the present study was to establish the exploratory factorial structure of instruments that measured psychological-cultural variables around intentions and experiences related to the interruption of pregnancy. A non-experimental, exploratory and cross-sectional study was carried out with a non-probabilistic selection of 100 students. The adjustments of the theoretical relationships with respect to the weighted relationships were estimated using two structural models, one cultural and the other cognitive. The values factor explained 41% of the variance (α = 0.732). The belief factor explained 33% of the variance (α = 0.705). The perceptual factor explained 28% of the variance (α = 0.721). The motive factor explained 23% of the variance (α = 0.742). The attitudinal factor explained 17% of the variance (α = 0.701). The normative factor explained 14% of the variance (α = 0.758). The intentional factor explained 9% of the variance (α 0.784) and the experiential factor explained 7% of the variance (α = 0.791). However, the fit and residual parameters [X2 = 356.46 (67df) p = 0.067; GFI = 0.990; CFI = 0.975; RMSEA = 0.000] of the structural model of dependency relationships between indicators and cultural factors evidenced the spurious incidence of perceptions about experiences of termination of pregnancy (β = 0.27). In contrast, the adjustment and residual statistics [X2 = 145.25 (46df) p = 0.035; GFI = 0.970; CFI = 0.985; RMSEA = 0.003] of the cognitive model showed the significant effect of attitudes on intentions to terminate pregnancy (β = 0.68).

APA, Harvard, Vancouver, ISO, and other styles

34

Sheinis, L. "Richardière. La variole pendant la grossesse à l’Hôpital d’Aubervilliers pendant l’année 1892. (Union Médicale, №№ 22 et 23, 1893). Smallpox during pregnancy." Journal of obstetrics and women's diseases 7, no. 5 (September 22, 2020): 422–24. http://dx.doi.org/10.17816/jowd75422-424.

Full text

Abstract:

According to most authors, smallpox during pregnancy is especially dangerous for the mother and even more for the fetus; death of the fetus, interruption of pregnancy, and after childbirth bleeding and infection, often leading to a fatal outcome - these are the sad results attributed to the influence of this disease on pregnancy and the fetus, not to mention the fact that pregnancy in turn is reflected in a disastrous way on the very course of smallpox, predisposing to the hemorrhagic form of this disease.

APA, Harvard, Vancouver, ISO, and other styles

35

Kramov, N. "Pregnancy and tuberculosis Levy-Lѳnz (Z. f. D. G. Tub. Z. H. 11)." Kazan medical journal 32, no. 10-11 (October 2, 2021): 984. http://dx.doi.org/10.17816/kazmj80813.

Full text

Abstract:

Levy-Lѳnz (Z. f. D. G. Tub. Z. H. 11), - considering pregnancy an unfavorable factor in the course of pulmonary TB, sees in artificial interruption not a remedy, but only liberation from the harmful influence b.

APA, Harvard, Vancouver, ISO, and other styles

36

Partridge, Ann, Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro A. Peccatori, Hatem A. Azim, Marco Colleoni, et al. "Abstract GS4-09: Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13)." Cancer Research 83, no. 5_Supplement (March 1, 2023): GS4–09—GS4–09. http://dx.doi.org/10.1158/1538-7445.sabcs22-gs4-09.

Full text

Abstract:

Abstract Background: Pregnancy after breast cancer (BC) is of substantial importance for many young women at diagnosis and during follow-up. BC treatment including standard endocrine therapy (ET) (5-10 years) may reduce ovarian reserve and the chances of subsequent successful pregnancy, given conception is contraindicated during ET. A temporary interruption of ET to attempt and carry a pregnancy in this population has never been prospectively studied. Methods: POSITIVE is a single-arm, prospective, investigator-initiated, international trial evaluating the safety and pregnancy outcomes of interrupting ET for young women with early-stage hormone-receptor-positive (HR+) BC who desire pregnancy. The primary objective is to assess the risk of BC relapse associated with ET interruption for ~2 years to achieve pregnancy. Women ≤42 years with stage I-III HR+ BC who received adjuvant ET (SERM alone, GnRH analogue plus SERM or AI) for 18 to 30 months and wished to interrupt ET to attempt pregnancy were eligible. The primary endpoint is breast cancer free interval (BCFI) defined as the time from enrollment to the first BC event (local, regional, distant recurrence or a new invasive contralateral BC). Planned sample size was 500 patients. Three interim analyses of BCFI were reviewed by the Data Safety Monitoring Committee (DSMC) to assure a 95% chance of stopping the trial early if the annual BCFI event rate exceeded 4%; with primary analysis triggered after 1600 patient years of follow-up (pyfu) and no more than 46 BCFI events defined as the safety threshold. The DSMC recommended continuing the study following each interim analysis. We now report the primary results. Results: From 12/2014 to 12/2019, 518 women were enrolled. At enrollment, the median age of participants was 37 years (27-43 years); 75.0% were nulliparous, 93.4% had stage I/II disease, 66.3% node-negative. Median time from BC diagnosis to enrollment was 29 months (IQR: 25-32). Tamoxifen alone was the most prescribed ET (41.7%), followed by tamoxifen+ovarian function suppression (35.7%). 62.0% of participants had received neo/adjuvant chemotherapy. At a median follow-up of 41 months (1638 pyfu), 44 participants had experienced a BCFI event, not exceeding the pre-specified safety threshold of 46 events. The 3-year BCFI failure percent was 8.9% (95% CI: 6.3 to 11.6%), similar to the 9.2% (95% CI: 7.6 to 10.8%) calculated in the comparative external control cohort from the SOFT/TEXT trials (Sun et al, Breast 2020). Of 497 women followed for pregnancy status, 368 (74.0%) had at least one pregnancy, 317 (63.8%) had at least one live birth, with a total of 365 babies born. Based on competing risk analysis, 76.3% of patients resumed ET (half within 26 months), 8.3% had BCFI event/death before ET resumption, and 15.4% had not resumed ET yet. Conclusions: The POSITIVE trial demonstrates that for young women with early HR+ BC desiring pregnancy, temporary interruption of ET to attempt pregnancy does not confer a greater short-term risk of recurrence than that observed in a modern historical control group that did not interrupt ET. Most participants have had a live birth. Further follow-up is planned to confirm long-term safety. These results should be considered in counselling BC patients desiring future pregnancy. Citation Format: Ann Partridge, Olivia Pagani, Samuel M. Niman, Monica Ruggeri, Fedro Alessandro A. Peccatori, Hatem A. Azim, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna Saetersdal, Judith Kroep, Audrey Mailliez, Ellen Warner, Virginia F. Borges, Frédéric Amant, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong Eon Lee, Janice Walshe, Manuel Ruiz Borrego, Halle Moore, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Karen L. Smith, Teresa Ferreiro Vilarino, Karin Ribi, Kathryn Ruddy, Sarra El-Abed, Martine Piccart, Larissa A. Korde, Aron Goldhirsch, Richard D. Gelber. Pregnancy Outcome and Safety of Interrupting Therapy for women with endocrine responsIVE breast cancer: Primary Results from the POSITIVE Trial (IBCSG 48-14/BIG 8-13) [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr GS4-09.

APA, Harvard, Vancouver, ISO, and other styles

37

Klimatckaia, Liudmila G., and Tatyana V. Dolgolenko. "Interruption of pregnancy: medical, social and legal problems in Russian society." HIGHER SCHOOL’S PULSE 10, no. 2 (July 30, 2016): 31–33. http://dx.doi.org/10.5604/20812021.1208713.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Watts, D. H., M. Lu, B. Thompson, R. E. Tuomala, W. A. Meyer, H. Mendez, K. Rich, et al. "Treatment Interruption after Pregnancy: Effects on Disease Progression and Laboratory Findings." Infectious Diseases in Obstetrics and Gynecology 2009 (2009): 1–8. http://dx.doi.org/10.1155/2009/456717.

Full text

Abstract:

Objective. To assess clinical progression and inflammatory markers among women stopping or continuing antiretroviral therapy (ART) after pregnancy.Methods. ART-naïve women with CD4+ lymphocyte counts >350 cells/uL initiating ART during pregnancy had clinical events and laboratory markers compared over one year postpartum between those stopping (n=59) or continuing (n=147) ART.Results. Slopes in CD4 count and HIV RNA did not differ between groups overall and in subsets of ZDV or combination therapy. The hazard ratio (HR) of a new class B event was 2.09 (95% CI 0.79–5.58) among women stopping ART, 1.24 (0.31–4.95) in those stopping ZDV, and 2.93 (0.64–13.36) among those stopping combination therapy. Women stopping ART had increased immune activation. No significant differences were seen in C-reactive protein, lipids, leptin, or interleukin-6.Conclusions. While changes in CD4 and HIV RNA levels over one year were similar between women stopping or continuing ART postpartum, higher immune activation among women stopping therapy requires further study.

APA, Harvard, Vancouver, ISO, and other styles

39

Shivalingappa, H., N. D. Satyanarayan, and M. G. Purohit. "Antiimplantation and pregnancy interruption efficacy of Rivea hypocrateriformis in the rat." Journal of Ethnopharmacology 74, no. 3 (March 2001): 245–49. http://dx.doi.org/10.1016/s0378-8741(00)00372-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Gubareva, L. I. "Psychoneuroendocrine status of women with the threat of interruption of pregnancy." International Journal of Psychophysiology 131 (October 2018): S100—S101. http://dx.doi.org/10.1016/j.ijpsycho.2018.07.278.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Haspels, A. A. "Interruption of early pregnancy by an anti-progestational compound, RU 486." European Journal of Obstetrics & Gynecology and Reproductive Biology 20, no. 3 (September 1985): 169–75. http://dx.doi.org/10.1016/0028-2243(85)90016-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Gómez Morales, Oscar Alberto, Moises Echazarreta Sosa, and Julio Cesar Llauger Montes. "Incomplete mole in term pregnancy: a case report and literature review." Obstetrics & Gynecology International Journal 13, no. 3 (June 30, 2022): 174–76. http://dx.doi.org/10.15406/ogij.2022.13.00646.

Full text

Abstract:

A clinical case of a 24-year-old female is presented, which by first-trimester obstetric ultrasound data suggestive of an incomplete mole is detected, first-trimester screening is performed, reporting a fetus without structural alterations, pregnancy interruption is offered, the same as the patient refuses, pregnancy is continued until the end of 37 weeks of gestation; where a fetus is obtained phenotypically without structural malformations.

APA, Harvard, Vancouver, ISO, and other styles

43

Chelysheva, Ekaterina, Jane Apperley, Elisabetta Abruzzese, Dong-Wook Kim, Konstantin Kotlyarchuk, Oleg Shukhov, and Anna G. Turkina. "Kinetics of the Leukemic Clone in Patients with Chronic Myeloid Leukemia during Pregnancy." Blood 132, Supplement 1 (November 29, 2018): 4254. http://dx.doi.org/10.1182/blood-2018-99-115984.

Full text

Abstract:

Abstract Background Observation without treatment in chronic myeloid leukemia (CML) is suggested only for patients (pts) with a durable and stable deep molecular response (DMR). However, CML women with various grade of molecular response usually stop tyrosine kinase inhibitors (TKIs) for conception/pregnancy and/or breastfeeding. The kinetics of the leukemic clone during these long interruptions needs to be understood in order to provide the optimal recommendations for the pts. Aim To analyze the loss and recovery of molecular response in CML pts with initial major molecular response (MMR) and deep molecular response (DMR) who had TKI interruptions during pregnancy. Patients and methods Pregnancy cases of women with BCR-ABL p210 transcript CML chronic phase and at least MMR before TKI interruption were included; cases with insufficient follow-up and previous bone marrow transplantation were excluded. Only cases with "ongoing pregnancy" or at term for pregnancy were evaluated as they had a valid off-treatment period. Data were obtained from observational studies of CML and pregnancy, like the CML pregnancy registries of Russian hematology society, and other institutional databases. Pregnancy cases were divided into 3 groups according to the molecular response before TKI interruption: 1) with DMR and "stop" criteria; 2) with DMR and no "stop" criteria; 3) with MMR only. DMR, MMR and molecular response 2 (MR2) were considered as BCR-ABL≤0,01%; BCR-ABL>0,01% and ≤0,1%; BCR-ABL>0,1% and ≤1% accordingly by international scale (IS). "Stop" criteria were considered as the main inclusion criteria of EURO-SKI multicenter "stop" trial: 1) treatment by TKIs for ≥3 years,2) stable DMR for ≥1 year before TKI cessation. Probability of MMR loss and recovery were evaluated by Cumulative incidence function (CIF) using Gray test for comparison. TKI restart without MMR loss and death were considered as competitors. The proportion of pts with MR2 loss during TKI interruption was additionally assessed. Results In total 227 pregnancies from 172 CML pts were evaluated and 87 cases were eligible for the analysis. Distribution by groups was as follows: 39, 26 and 22 cases in group 1, 2 and 3 accordingly. Median (Me) time without TKI therapy was 8 months (mo)(range 1-54) (table 1). In 72 (83%) cases TKIs were restarted after MMR loss (n=58) and without MMR loss (n=14). TKIs were restarted after and during pregnancy in 54 and 18 cases correspondingly. Imatinib and nilotinib were used at late pregnancy (2nd-3rd trimester) in 15 and 3 cases; no birth defects were observed. Seven pts got IFN during TKI interruption. TKIs were not restarted in 15 (17%) cases: 14 pts with DMR remained off-treatment after labour for a median of 29 mo (range 3-54) and in 1 pt with MMR loss pregnancy is ongoing. Cumulative incidence (CI) of MMR loss at 6 and 12 mo after TKI cessation was 57% and 66%, and CI of MMR recovery at 6 and 12 mo after TKI restart was 50% and 75% in the whole cohort. CI of MMR loss at 6 and 12 mo was 35%, 65%, 86% and 46%, 76%, 86% in group 1,2 and 3 accordingly. CI of MMR recovery at 6 and 12 mo was 75%, 55%, 23% and 100%, 73% and 55% in group 1,2 and 3, respectively. CI of MMR recovery in group 2 and 3 at 24 mo after TKI restart was 86% and 78%. Significant differences (p<0,05%) were found between all groups for MMR loss and MMR recovery except the MMR recovery rates between groups 2 and 3 (figure 1). In 45 (52%) cases MR2 was lost simultaneously with MMR loss or after it (table 1). In 4 (5%) cases a complete hematologic response (CHR) was lost after MR2 loss; however, a MMR was regained in 2 of 4 pts. Two more pts with MR2 and CHR loss died later from progression of CML: 6 mo and approximately 8 years after labour. Both of them were non-compliant to therapy and stopped treatment again by self-made decisions with no control follow-up. Conclusions CML pts with DMR and "stop" criteria have the best chance to keep MMR during pregnancy after TKI cessation and may remain without treatment after labour. MMR is lost in the majority of pts with MMR/DMR and no "stop" criteria. However, the loss of response is reversible and MMR can be recovered within 1-2 years after TKI resuming in spite of even MR2 loss. Our data confirm the option for planning pregnancy not only in CML pts with stable DMR but also in pts who have a MMR only or non-stable DMR followed up by a careful molecular monitoring during and after pregnancy. The use of TKI during at late pregnancy will be discussed. Disclosures Chelysheva: Novartis: Other: provided consultations and performed lectures; Bristol Myers Squibb: Other: provided consultations and performed lectures; Fusion Pharma: Other: provided consultations . Apperley:Incyte: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau. Abruzzese:Pfizer: Consultancy; Novartis: Consultancy; BMS: Consultancy; Ariad: Consultancy. Kim:Pfizer: Research Funding; Novartis: Research Funding; Ilyang: Research Funding; BMS: Research Funding. Shukhov:Bristol Myers Squibb: Other: provided consultations and performed lectures ; Novartis: Other: provided consultations and performed lectures . Turkina:Novartis: Other: provided consultations; Bristol Myers Squibb: Other: provided consultations; Phizer: Other: provided consultations; Fusion Pharma: Other: provided consultations.

APA, Harvard, Vancouver, ISO, and other styles

44

Lee, Jeong-Ok, Dong-Wook Kim, Elisabetta Abruzzese, Jane Apperley, Louise Caldwell, and Michael J. Mauro. "Kinetics of BCR-ABL after TKI Interruption during Pregnancy in CML: A Multinational Retrospective Analysis." Blood 132, Supplement 1 (November 29, 2018): 4263. http://dx.doi.org/10.1182/blood-2018-99-119615.

Full text

Abstract:

Abstract Introduction: Pregnancy requires, and is an important motivator of tyrosine kinase inhibitor (TKI) cessation in patients with chronic myeloid leukemia (CML). While conventional treatment free remission (TFR) attempts may allow observation of limited rise in BCR-ABL prior to expected TKI re-exposure, TKI cessation in pregnancy affords longer observation of BCR-ABL kinetics without automatic TKI re-exposure. Mathematical models and clinical observation of BCR-ABL kinetic rise during TKI discontinuation or planned cessation estimate of 'doubling time' (DT) of roughly 9 days (Branford et al., Blood 2012). In order to explore the impact of pregnancy, we studied BCR-ABL kinetics and response stability during and after pregnancy. Methods: We collected cases of successful pregnancies (conception->childbirth) at 4 CML referral centers including the following conditions: 1/conception occurring while on TKI therapy; 2/TKI therapy stopped for the purpose of conception; and 3/ pregnancy during TKI cessation within a TFR clinical trial. Cases with early spontaneous/elective abortion, treated with interferon during pregnancy or with less than 2 BCR-ABL transcripts recorded during pregnancy were excluded. Doubling time (DT) was calculated using the following formula: DT = ln2/k, where k = (ln(b)-ln(a))/d, where (a) and (b) is the value before the rise and at the rise, and (d) is days. Results: In total 50 pregnancies in 39 patients were analyzed; 10 patients had >1 pregnancy. Four pregnancies were in the context of TFR study (2 enrolled at conception, 1 patient 28mo in TFR, 1 patient 5mo in TFR). The majority of cases were on first-line treatment at TKI cessation and median duration of TKI therapy was 6.4 years (range 0.5-16.2); 58% were in deeper molecular response (MR4 or deeper) and 34% in major molecular response (MMR) at TKI cessation. Patient characteristics are summarized in Table 1. Median time off TKI was 10.1 months (range 5.4-71.5). Of 44 pregnancy cases within MMR or deeper at TKI cessation, 54.5% maintained MMR or greater; 60.7% of those in MR4 or deeper and 43.7% for those in MMR, respectively. Several cases were associated with decline in BCR-ABL off TKI: 2 cases of improvement from MMR to deep MR (MR5), and among 4 cases not in MMR at TKI cessation, 1 achieved MMR during pregnancy (Table 2). BCR-ABL rise in 2 or more consecutive measurements, and at least one measurement of rise defined as more than 2-fold increase, was observed in 24 patients. The median BCR-ABL doubling time among 54 such instances in these 24 patients was 18.3 days (range 1.8-306.8). Of 20 cases that lost MMR during pregnancy, 17 met these criterions for BCR-ABL rise; the median doubling time among 40 such instances in these cases was 14.7 days (1.8-306.8). Postpartum (n=48), 34 cases have been retreated to date; 14 others remain off therapy with ongoing deep MR (MR5) in 6 cases, MMR in 6 and BCR-ABL <1 (MR2) in 2. Of the 34 cases of retreatment, 5 were not evaluable due to limited time back on TKI (n=3), immediate re-cessation of TKI due to second pregnancy (n=1) or loss of follow-up (n=1). Of the 29 evaluable cases, to date 22 achieved deep MR (MR4 or greater) and 7 achieved MMR. Three patients deemed to not respond adequately after prior TKI resumption switched TKI and achieved MMR or deeper. Conclusions: BCR-ABL doubling time during TKI cessation for pregnancy was slower compared with that of non-pregnant patients with TKI cessation (TFR) or interruption historically. This retrospective analysis of pregnancy-associated TKI cessation demonstrates overall favorable response stability, with observation of high rates of MMR retention, slowing of BCR-ABL kinetic increase after initial rise, and rare cases of deepening remission over time off TKI. Overall kinetics of BCR-ABL appears variable during pregnancy associated TKI cessation. Given the prominence of pregnancy and family planning as a consideration for TFR attempt and these data, further study of the impact of pregnancy on CML biology, immune function, and relapse risk is warranted. Disclosures Kim: BMS: Research Funding; Ilyang: Research Funding; Pfizer: Research Funding; Novartis: Research Funding. Abruzzese:Ariad: Consultancy; Novartis: Research Funding; BMS: Consultancy; Pfizer: Consultancy. Apperley:Incyte: Honoraria, Speakers Bureau; BMS: Honoraria, Speakers Bureau; Pfizer: Honoraria, Speakers Bureau; Novartis: Honoraria, Research Funding, Speakers Bureau. Mauro:Pfizer: Consultancy; Novartis: Consultancy, Research Funding; Takeda: Consultancy; Bristol-Myers Squibb: Consultancy.

APA, Harvard, Vancouver, ISO, and other styles

45

Romanenko, I. Yu. "Obstetric and perinatal outcomes in women with threatened interruption of pregnancy, living in the armed conflict zone." HEALTH OF WOMAN, no. 2(148) (March 30, 2020): 21–24. http://dx.doi.org/10.15574/hw.2020.148.21.

Full text

Abstract:

The objective: was to evaluate the course of pregnancy, childbirth and perinatal outcomes of delivery of women with threatened interruption of pregnancy (TIP), living in the Lugansk region, to improve treatment and preventive measures and prevent obstetric and perinatal complications in such women. Materials and methods. A prospective clinical and statistical analysis of the course of pregnancy and childbirth of 86 pregnant women in first and second trimesters of pregnancy were hospitalized regarding TIP in the hospitals located in the Luhansk region was performed (group I). The control group consisted of 64 pregnant women with non-complicated obstetric anamnesis and physiological course of pregnancy with similar gestational period of pregnancy and place of residence (group II). Results. In women of group I, a history of female genital inflammatory diseases was significantly more frequent, and a complicated course of pregnancy and childbirth was registered. The number of cases of acute respiratory viral infection (ARVI) was in 4, isthmic-cervical insufficiency (ICI) was in 3 times more often than in healthy pregnant women, asymptomatic bacteriuria, recurring TIP, gestational pyelonephritis and ureaplasma infection were found only in pregnant women of group I, the number of cases of anemia there was no significant difference. 13 (15.12%) of women of group I and 3 (4.69%) of group II (p=0.041) had spontaneous preterm birth at 33–37 weeks of gestation; operative delivery was registered in 23 (26.74%) and 8 (12.50%) cases, respectively (p=0.033). It was established that recurrent TIP, ARVI during this pregnancy, ICI, gestational pyelonephritis are statistically significant risk factors for preterm delivery and operative delivery. Premature rupture of the membranes was found in 1.58, weakness of labor – in 2.2, premature detachment of a normally located placenta – in 6, fetal distress – in 1.9 times more often in women of group I, central placenta previa was noted only in group I. Conclusions. The complicated course of the first and second trimesters of pregnancy, in particular, recurrent TIP, ARVI during this pregnancy, ICI, gestational pyelonephritis, had a direct effect on frequency increase of premature termination of pregnancy and operative delivery in patients of the main group compared with women of the control group. The presence of a history of chronic female genital inflammatory diseases, sexually transmitted infections, ARVI during this pregnancy, TIP in the first and second trimesters, allows pregnant women to be at high risk of developing gestational complications in order to conduct timely treatment. Key words: pregnancy, the threat of abortion, childbirth, the condition of newborns.

APA, Harvard, Vancouver, ISO, and other styles

46

Saha, Eti, Jharna Das, Mollik Moniruzzaman, and Citta Ranjan Bachher. "Laparoscopic Management of Tubal Ectopic of Heterotopic Pregnancy." Journal of Bangladesh College of Physicians and Surgeons 34, no. 4 (May 7, 2017): 218–21. http://dx.doi.org/10.3329/jbcps.v34i4.32490.

Full text

Abstract:

A heterotopic pregnancy is a rare complication of pregnancy in which both extra-uterine (ectopic pregnancy) and intrauterine pregnancy occur simultaneously. The prevalence of heterotopic pregnancy is estimated at 0.6- 2.5: 10,000 pregnancy. It is a challenge for obstetrician to manage the tubal pregnancy without interruption of intrauterine pregnancy. Here we describe a case who had left tubal alive ectopic pregnancy & also intrauterine alive pregnancy simultaneously after a natural conception. This patient was managed successfully with laparoscopic left salpingectomy, and intrauterine pregnancy has been continuing. There are some precautions during laparoscopic procedure & post operative period which can help for continuation of intrauterine pregnancy. In our clinical experience, this is an extreme rare disorder and we feel interest to report this case. A heterotopic pregnancy can result from a natural conception; it requires a high index of suspicious for early and timely diagnosis; a timely intervention can result in a successful outcome of the intrauterine fetus.J Bangladesh Coll Phys Surg 2016; 34(4): 218-221

APA, Harvard, Vancouver, ISO, and other styles

47

Kosheleva, N. G., V. M. Prokopenko, P. S. Buzurukova, T. P. Vosheva, T. M. Krol, and G. M. Khoroshilova. "Significance of hypomagneemia in obstetrical practice and application of Magne V6." Journal of obstetrics and women's diseases 46, no. 1 (November 15, 1997): 30–33. http://dx.doi.org/10.17816/jowd80497.

Full text

Abstract:

Exchange of a magnesium at 78 pregnant women with threat of interruption of pregnancy, hestosis in light form, diabetus mellitus of 1-th type of light form. Magne V6 was included in complex treatment of 40 pregnant women with a main pathology. Magne V6 was applied on 2 tablets 3 times per a day during 8 days. In an outcome of treatment normalization of a balance M G2 + in an organism was marked: raisedlnitially reduced level M G2 + in blood and was reduced a little экскреция of a magnesium with urine. By comparison of exchange M G2 + with CPO the best outcomes are obtained there, where CPO was increased. Metrics CPO were redused after treatment by Magne V6 at all these pregnant women. Magne V6 it is possible to recommend for treatment of threat of interruption of pregnancy, hestosis (oedima of a pregnant women, nephropathy of 1 -st),diabetus mellitus.

APA, Harvard, Vancouver, ISO, and other styles

48

Santarelli, Natalia, and Claudia Cecilia Anzorena. "Experiencias emocionales y significaciones en torno al embarazo no deseado/aborto voluntario. Aportes a los alcances de la causal salud integral para la interrupción legal del embarazo en Argentina." Clivajes. Revista de Ciencias Sociales, no. 14 (April 3, 2021): 206. http://dx.doi.org/10.25009/clivajes-rcs.v0i14.2673.

Full text

Abstract:

El artículo profundiza en la comprensión de las experiencias de malestar emocional de mujeres que transitan embarazos no deseados, seguidos de abortos, con el fin de aportar al debate sobre los alcances de la causal salud integral –que reconoce (o debería reconocer) el derecho a interrumpir legalmente un embarazo en el sistema de salud– en Argentina, a partir de una investigación cualitativa con perspectiva de género, feminista, durante la cual se entrevistó a 20 mujeres que abortaron clandestinamente, con medicamentos, en San Luis y Mendoza.Atiende la configuración emocional y las significaciones que asocian, al embarazo no deseado, su posible continuación o interrupción en determinadas condiciones y circunstancias personales, relacionales, sociales y legales. Distingue, emocionalmente, sorpresa, negación y aversión frente al embarazo; desesperación y urgencia por solucionar el problema; temor y miedo ante una práctica clandestina, así como vergüenza y culpa, vinculadas a mandatos sobre la sexualidad femenina, además del hecho de que, mientras el embarazo no deseado se considera ajeno, invasivo y torturante –lo cual denota afectación a la salud emocional–, su interrupción voluntaria se vive como el medio más adecuado para poner fin a los sufrimientos asociados. Concluye que estas configuraciones emocionales deben ser consideradas, por los equipos de salud y la sociedad, como parte de la causal salud integral para la interrupción legal del embarazo.Palabras clave: Embarazo no deseado, Salud mental, Interrupción legal del embarazo, Argentina Emotional experiences and meanings around unwanted pregnancy / voluntary abortion. Contributions to the scope of the integral health causal factor for the legal interruption of pregnancy in ArgentinaSummaryThe article delves into the understanding of the experiences of emotional distress of women who go through unwanted pregnancies, followed by abortions, in order to contribute to the debate on the scope of the integral health causal - which recognizes (or should recognize) the right to legally interrupt a pregnancy in the health system - in Argentina. It is based on a qualitative research with a gender perspective, feminist, during which 20 women who had clandestinely aborted, with medication, were interviewed in San Luis and Mendoza.It attends to the emotional configuration and the meanings associated with the unwanted pregnancy, its possible continuation or interruption under certain personal, relational, social and legal conditions and circumstances. It distinguishes, emotionally, surprise, denial and aversion to pregnancy; desperation and urgency to solve the problem; fear and dread of a clandestine practice, as well as shame and guilt, linked to mandates on female sexuality. In addition to the fact that, while unwanted pregnancy is considered alien, invasive and torturous - which denotes affectation to emotional health -, its voluntary interruption is seen as the most suitable means to put an end to the associated sufferings. It concludes that these emotional configurations should be considered, by health teams and society, as part of the integral health cause for the legal interruption of pregnancy.Keywords: Unwanted pregnancy, Mental health, Legal termination of pregnancy, Argentina Expériences émotionnelles et significations autour de la grossesse non désirée/ avortement volontaire. Des apports sur les portées du motif de la santé intégrale pour l’interruption légale de la grossesse en ArgentineRésuméL’article approfondie sur la compréhension des expériences du mal être émotionnel des femmes qui transitent par des grossesses non désirées suivies d’avortements afin d’apporter au débat sur les portées du motif de la santé intégrale –qui reconnaît (ou devrait reconnaître) le droit à interrompre légalement une grossesse dans le système de santé- en Argentine, à partir d’une recherche qualitative avec approche de genre, féministe, pendant laquelle on a interviewé à 20 femmes qui ont avorté clandestinement à l’aide des médicaments à San Luis y Mendoza.Il aborde la configuration émotionnelle et les significations qui associent, à la grossesse non désirée, sa possible continuation ou interruption dans certaines conditions et circonstances personnelles, relations sociales et légales. Il distingue, émotionnellement, surprise, négation et aversion face à la grossesse, désespoir et urgence pour résoudre le problème ; peur et larmes face à une pratique clandestine, ainsi que la honte et la culpabilité liées à des mandats sur la sexualité féminine, en plus du fait qu’alors que la grossesse non désirée est considérée étrangère, invasive et torturante – ce qui dénote affectation à la santé émotionnelle- son interruption volontaire se vit comme le moyen le plus adéquat pour mettre fin aux souffrances associées. On conclue que ces configurations émotionnelles doivent être considérées, par les équipes de santé et par la société comme une partie du motif de la santé intégrale pour l’interruption légale de la grossesse.Mots clés : Grossesse non désiré, Santé mentale, Interruption légale de la grossesse, Argentine

APA, Harvard, Vancouver, ISO, and other styles

49

WATERS, C. A., B. SINGH, and L. HONORE. "An Activity Derived From Rabbit Serum Causing Interruption of Pregnancy in Mice." American Journal of Reproductive Immunology and Microbiology 7, no. 1 (January 1985): 7–14. http://dx.doi.org/10.1111/j.1600-0897.1985.tb00256.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Silvestre, Louise, Catherine Dubois, Maguy Renault, Yvonne Rezvani, Etienne-Emile Baulieu, and André Ulmann. "Voluntary Interruption of Pregnancy with Mifepristone (RU 486) and a Prostaglandin Analogue." New England Journal of Medicine 322, no. 10 (March 8, 1990): 645–48. http://dx.doi.org/10.1056/nejm199003083221001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!